News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The new campus has been designed as an employee-centred experience and ecosystem zone
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Automated parallel capillary electrophoresis system simplifies protein analysis
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Subscribe To Our Newsletter & Stay Updated
